Back to articles

Ernexa Plants Flag in Texas: A New Front in the War Against Ovarian Cancer

Leila Cohen•May 14, 2025
An artist's rendering of engineered iMSCs (induced mesenchymal stem cells) actively targeting and surrounding ovarian cancer cells, with a subtle overlay of the Texas state outline in the background, symbolizing the new subsidiary's role.
  • Ernexa Therapeutics establishes ErnexaTX2, a new Texas subsidiary, to advance its fight against aggressive cancers.
  • The move strategically positions the company for pivotal clinical trials of ERNA-101, its lead therapy for ovarian cancer, anticipated for 2026.
  • This expansion underscores Ernexa's commitment to revolutionizing cancer treatment with its innovative "off-the-shelf" cell therapies.

In a bold stride towards conquering one of women's deadliest adversaries, Ernexa Therapeutics (NASDAQ: ERNA) today announced a significant expansion, planting its roots deep in the heart of Texas with the formation of ErnexaTX2. This wholly owned subsidiary isn't just a new office; it's a war room for the development of ERNA-101, a revolutionary cell therapy poised to redefine the battle against ovarian cancer1, 4, 7.

Ovarian cancer, a formidable foe often resistant to current treatments, faces a new challenger in ERNA-1015, 7. Developed from Ernexa's groundbreaking iPSC-to-iMSC technology, this therapy promises a scalable, "off-the-shelf" solution, designed to supercharge the body's own immune system to hunt down and destroy cancer cells4. The move to Texas is a calculated one, laying the critical groundwork for clinical manufacturing, regulatory navigation, and patient access as ERNA-101 races towards first-in-human studies slated for 20261, 3.

Sanjeev Luther, President and CEO of Ernexa, declared, "As we continue to progress ERNA-101 through key preclinical milestones, we’re also setting the stage for a seamless transition into clinical work. The formation of ErnexaTX2 reflects both our long-term commitment to the Texas ecosystem and our strategic readiness"1. This strategic positioning is further bolstered by a collaboration with renowned cell therapy expert Dr. Michael Andreeff, aiming to unlock new strategies against the tumor microenvironment1.

With IND-enabling studies for ERNA-101 on track for 2025, Ernexa is not just building a subsidiary; it's building hope for countless patients, marking a new dawn in the fight against advanced cancers and autoimmune diseases3.

References

  1. www.biospace.com
  2. www.globenewswire.com
  3. www.stocktitan.net
  4. www.ernexatx.com
  5. www.insideprecisionmedicine.com
  6. www.stocktitan.net
  7. www.globenewswire.com
  8. www.globenewswire.com

Stay Updated!

Get the latest biotech and pharma news delivered to your inbox.